08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year. This year...
07:00 , Jun 29, 2015 |  BC Week In Review  |  Clinical News

DCR-MYC: Additional Phase I data

Data from 18 evaluable patients with solid tumors, multiple myeloma or lymphoma in an open-label, dose-escalation, U.S. Phase I trial showed that 0.1-0.68 mg/kg IV DCR-MYC on days 1 and 8 of each 21-day cycle...
07:00 , Jun 1, 2015 |  BC Week In Review  |  Clinical News

DCR-MYC: Interim Phase I data

Interim data from 19 patients with solid tumors, multiple myeloma or lymphoma in an open-label, dose-escalation, U.S. Phase I trial showed that 0.1-0.3 mg/kg IV DCR-MYC on days 1 and 8 of each 21-day cycle...
07:00 , May 25, 2015 |  BC Week In Review  |  Clinical News

DCR-MYC: Phase I ongoing

Dicerna said the open-label, dose-escalation, U.S. Phase I trial of IV DCR-MYC will now include an expansion cohort of patients with advanced pancreatic neuroendocrine tumors (PNETs). The addition is based on early signs of clinical...
08:00 , Feb 9, 2015 |  BC Week In Review  |  Clinical News

DCR-MYC: Phase Ib/II started

Dicerna began an open-label, international Phase Ib/II trial to evaluate IV DCR-MYC on days 1 and 8 of a 21-day cycle in about 72 patients with locally advanced unresectable or metastatic HCC. The trial will...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Clinical News

DCR-MYC: Phase I started

Dicerna began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV DCR-MYC, with a starting dose of 0.1 mg/kg, given on days 1, 8 and 15 in 28-day cycles in about 66 patients with...
02:18 , Jan 30, 2014 |  BC Extra  |  Top Story

Dicerna, Celladon price IPOs

RNAi play Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) and gene therapy company Celladon Corp. (NASDAQ:CLDN) both raised money in IPOs on Wednesday. Dicerna raised $90 million through the sale of 6 million shares at $15, which values...
01:47 , Jan 29, 2014 |  BC Extra  |  Financial News

Dicerna, Celladon, Eagle amend IPOs

RNAi play Dicerna Pharmaceuticals Inc. (Watertown, Mass.), gene therapy company Celladon Corp. (San Diego, Calif.) and drug delivery company Eagle Pharmaceuticals Inc. (Woodcliff Lake, N.J.) all amended planned IPOs on NASDAQ. Dicerna bumped up both...
02:14 , Jan 22, 2014 |  BC Extra  |  Financial News

Argos, Dicerna set IPO terms

Immunotherapy company Argos Therapeutics Inc. (Durham, N.C.) and RNAi company Dicerna Pharmaceuticals Inc. (Watertown, Mass.) set IPO terms on Tuesday. Both companies are seeking to list on NASDAQ. Argos plans to sell 4.3 million shares...
00:17 , Jan 1, 2014 |  BC Extra  |  Top Story

Dicerna, Revance jump in IPO queue

RNAi company Dicerna Pharmaceuticals Inc. (Watertown, Mass.) and dermatology company Revance Therapeutics Inc. (Newark, Calif.) proposed IPOs on Tuesday, bringing to 10 the number of companies that have jumped in the IPO queue in the...